Connecticut 2022 Regular Session

Connecticut House Bill HB05275

Introduced
2/28/22  
Refer
2/28/22  
Report Pass
3/18/22  
Report Pass
3/18/22  
Refer
3/30/22  
Refer
3/30/22  
Report Pass
4/5/22  
Report Pass
4/5/22  
Refer
4/13/22  

Caption

An Act Prohibiting Certain Health Carriers From Requiring Step Therapy For Prescription Drugs Used To Treat Mental Or Behavioral Health Conditions.

Impact

The passage of HB05275 would represent a significant shift in healthcare policy in the state, specifically aimed at improving access to necessary medications for mental health treatment. Currently, patients may face barriers due to step therapy protocols that prolong their treatment regimens by mandating trials of less effective medications. This bill seeks to align state insurance regulations with best practices in mental healthcare, thereby promoting better health outcomes for individuals suffering from mental and behavioral issues.

Summary

HB05275 aims to prohibit certain health insurance carriers from requiring the use of step therapy for prescription drugs used to treat mental and behavioral health conditions. Step therapy is a protocol that prescribes a sequence of drugs to treat a condition, often requiring patients to try less expensive options before more expensive ones. This bill recognizes the unique challenges faced by individuals with mental health issues and aims to streamline their access to appropriate medications, ensuring they aren't forced to go through ineffective treatments before obtaining the most suitable care.

Sentiment

The sentiment surrounding HB05275 has generally been positive among mental health advocates, healthcare providers, and many lawmakers who argue that it will reduce unnecessary delays in treatment and allow healthcare providers to make more personalized medication decisions based on the needs of their patients. However, some opposition exists from insurance companies who express concerns about the potential impact on their costs and coverage protocols.

Contention

One of the notable points of contention is the balance between ensuring access to necessary medications and managing healthcare costs. Opponents of the bill argue that eliminating step therapy requirements could lead to increased healthcare costs for insurers and, by extension, consumers. Proponents, however, emphasize the importance of timely and effective treatment for mental health conditions, highlighting that prolonged ineffective treatment can lead to worsening health outcomes and increased long-term costs.

Companion Bills

No companion bills found.

Similar Bills

CT SB00182

An Act Prohibiting Certain Health Carriers From Requiring Step Therapy For Prescription Drugs Used To Treat A Mental Or Behavioral Health Condition Or A Chronic, Disabling Or Life-threatening Condition.

CT SB00394

An Act Concerning Requirements For Insurers' Use Of Step Therapy.

HI HB2194

Relating To Health Insurance.

HI SB2316

Relating To Health Insurance.

CT SB00022

An Act Limiting Cost-sharing For Prescription Drugs.

CT HB05517

An Act Concerning Cost-sharing For Prescription Drugs.

CT SB00025

An Act Concerning Out-of-pocket Expenses For Prescription Drugs.

HI SB218

Relating To Health Care Insurance.